Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
Escobar, Miguel, Agrawal, Neha, Chatterjee, Sagnik, Bhattacharya, Swastik, Caicedo, Jorge, Bullano, Michael, Schultz, Bob G.
Published in Journal of medical economics (31.12.2023)
Published in Journal of medical economics (31.12.2023)
Get full text
Journal Article
Cytomegalovirus related hospitalization costs among hematopoietic stem cell and solid organ transplant recipients treated with maribavir versus investigator-assigned therapy: A US-based study
Schultz, Bob G, Bullano, Michael, Paratane, Deepika, Rajagopalan, Krithika
Published in Transplant infectious disease (01.04.2024)
Published in Transplant infectious disease (01.04.2024)
Get full text
Journal Article
Healthcare costs among hemophilia A patients in the United States treated with rurioctocog alfa pegol (FVIII-PEG) or antihemophilic factor (recombinant), FC fusion protein (rFVIIIFc) using real-world data
Farahbakhshian, Sepehr, Fan, Qi, Schultz, Bob G., Princic, Nicole, Park, Julie, Bullano, Michael
Published in Journal of medical economics (31.12.2023)
Published in Journal of medical economics (31.12.2023)
Get full text
Journal Article
A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab
Batt, Katharine, Schultz, Bob G., Caicedo, Jorge, Hollenbeak, Christopher S., Agrawal, Neha, Chatterjee, Sagnik, Bullano, Michael
Published in Current medical research and opinion (03.10.2022)
Published in Current medical research and opinion (03.10.2022)
Get full text
Journal Article
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A
Bullano, Michael, Cool, Christina, Schultz, Bob G., Durgapal, Sneha, Sacks, Naomi, Liu, Yanmei, Kee, Rebecca, Batt, Katharine
Published in Expert review of pharmacoeconomics & outcomes research (07.02.2023)
Published in Expert review of pharmacoeconomics & outcomes research (07.02.2023)
Get full text
Journal Article
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France
Oppe, Mark, Muresan, Bogdan, Chan, Katie, Radu, Xenia, Schultz, Bob G., Turpin, Robin S., Nucit, Arnaud, Fenu, Elisabetta
Published in Expert review of pharmacoeconomics & outcomes research (07.02.2023)
Published in Expert review of pharmacoeconomics & outcomes research (07.02.2023)
Get full text
Journal Article
Cost‐effectiveness of maribavir versus conventional antiviral therapies for post‐transplant refractory cytomegalovirus infection with or without genotypic resistance: A US perspective
Schultz, Bob G., Kotton, Camille N., Jutlla, Ginita, Ressa, Riccardo, Lacey, Tam, Chowdhury, Emtiyaz, Bo, Tien, Fenu, Elisabetta, Gelone, Daniele K., Poirrier, Jean‐Etienne, Amorosi, Stacey L.
Published in Journal of medical virology (01.04.2024)
Published in Journal of medical virology (01.04.2024)
Get full text
Journal Article
Cost-effectiveness of intravenous vedolizumab vs subcutaneous adalimumab for moderately to severely active ulcerative colitis
Schultz, Bob G, Diakite, Ibrahim, Carter, John A, Snedecor, Sonya J, Turpin, Robin
Published in Journal of managed care & specialty pharmacy (01.11.2021)
Published in Journal of managed care & specialty pharmacy (01.11.2021)
Get full text
Journal Article
A real-world evidence analysis of the impact of switching from factor VIII to emicizumab prophylaxis in patients with hemophilia A without inhibitors
Escobar, Miguel, Bullano, Michael, Mokdad, Ali G., Caicedo, Jorge, Schultz, Bob G., Fan, Qi, Verma, Sumit
Published in Expert review of hematology (03.06.2023)
Published in Expert review of hematology (03.06.2023)
Get full text
Journal Article
Evaluating the impact of recombinant porcine factor VIII compared with activated recombinant factor VII on acquired hemophilia A outcomes
Batt, Katharine, Bullano, Michael, Schultz, Bob G, Liu, Yanmei, Kee, Rebecca, Harley, Carolyn, Cool, Christina
Published in Future Rare Diseases (30.06.2022)
Published in Future Rare Diseases (30.06.2022)
Get full text
Journal Article
Real-World Analysis of Healthcare Resource Utilization and Costs Among Patients Diagnosed with Von Willebrand Disease and Angiodysplasia
Connell, Nathan T., Caicedo, Jorge, Nieto, Natalia, Chatterjee, Sagnik, Hait, Arunima, Bullano, Michael, Gupta, Arun, Schultz, Bob G
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
S0819 Evaluating Cost Per Remission and Cost of Serious Adverse Events in Advanced Therapies for Ulcerative Colitis
Jairath, Vipul, Cohen, Russell D., Loftus, Edward V., Candela, Ninfa M., Lasch, Karen, Schultz, Bob G.
Published in The American journal of gastroenterology (01.10.2020)
Published in The American journal of gastroenterology (01.10.2020)
Get full text
Journal Article
A Real-World Study of Pre-Post Annualized Bleed Rates and All Cause Costs Among Non-Inhibitor Patients with Hemophilia a Switching from FVIII Prophylaxis to Emicizumab
Batt, Katharine, Schultz, Bob G, Caicedo, Jorge, Hollenbeak, Christopher S, Agrawal, Neha, Chatterjee, Sagnik, Dayma, Megha, Bullano, Michael
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
AMCP Partnership Forum: Digital Therapeutics-What Are They and Where Do They Fit in Pharmacy and Medical Benefits?
Published in Journal of managed care & specialty pharmacy
(01.05.2020)
Get full text
Journal Article